Tirzepatide Prices Are Falling

What actually changed in eight months

Three things moved, all in the same direction. Lilly cut self-pay vial pricing in December 2025, taking the 2.5 mg tier from $349 to $299 and the 7.5 mg-and-above tier from $499 to $449. The Medicare GLP-1 Bridge went live on 1 July 2026 at a flat $50 a month for eligible Part D beneficiaries. And the KwikPen reached self-pay pricing and national pharmacy pickup, removing the syringe objection from the brand route.

The Bridge is working faster than expected

On the earnings call Lilly's US president reported the Medicare Bridge is expanding access to roughly 35% more Americans, covering about 20 million eligible people, with a "significant inflection point" in prescriptions since 1 July and prior authorisation running smoothly. About 80% of new patients are choosing injectables over the oral option.

If you are on Medicare and paying cash for compounded tirzepatide, that is the single most important sentence on this page. A flat $50 for an FDA-approved product beats every compounded route on this site by a wide margin, and it did not exist eight months ago.

What this does to the compounded case

It narrows it at the top and leaves it intact at the bottom. At a 10 mg maintenance dose the cheapest verified compounded route is $199 against $449 for FDA-approved product through LillyDirect — still a substantial gap, but a much smaller one than the fourfold difference that existed when list price was the only brand comparison anyone quoted.

For a patient at the starter dose the gap is smaller again: $299 for an approved product against $199 at the cheapest compounded entry price. Anyone choosing compounded purely on price should re-run that comparison, because the answer has changed since most of the round-ups on the internet were written.

What did not change

Compounded preparations are still not FDA-approved and are still not reviewed by FDA for safety, effectiveness or quality before marketing. The brand price falling does not alter that distinction; it alters what the distinction costs you. When approval was a $600-a-month premium the trade-off was real for most budgets. At the current gap it is a different calculation, and for Medicare-eligible patients it has inverted entirely.

Where prices go next

Lilly expects the GLP-1 patient population to grow from roughly 20 million worldwide at the end of 2025 to about 30 million by the end of 2026, and flagged that medical-exception usage for Zepbound — which has propped up net pricing — is expected to decline as CVS returns it to formulary, lowering realised prices further. Volume growth is being bought with price concessions, deliberately.

The practical instruction for anyone on a compounded programme is to re-price annually rather than assuming today's comparison holds. Programmes do not notify existing patients when a competitor — or a manufacturer — drops below them. Our twelve-month projector and brand-versus-compounded calculator both run against the current dataset.

Tirzepatide Prices Are Falling: the shortest useful summary

Tirzepatide is a once-weekly injection titrated from 2.5 mg to a 15 mg ceiling in 2.5 mg steps at intervals of at least four weeks, producing roughly 15 to 21% mean weight reduction across the studied maintenance arms at 72 weeks and about 20% against semaglutide's 14% in the only head-to-head trial. It works while it is taken; the withdrawal evidence shows substantial regain after stopping. Compounded preparations cost from $133 a month and are not FDA-approved; brand product is approved and costs considerably more.

Those five facts decide most questions people arrive with. Everything else on this page is detail underneath them — which is worth reading before you spend $2,388 on a first year, but not worth confusing with the outline.

Tirzepatide Prices Are Falling: where to go next

If you have not chosen a program, price your expected maintenance dose with the projector rather than reading advertisements. If you have, check what it charges at 10 mg against the price-by-dose table. If you are struggling with side effects, the side-effect reference covers each one with reported frequencies and the red flags that need a clinician. And if a program has refused to name its pharmacy, the verification walkthrough explains why that single answer outranks any price difference.